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CORRESPONDENCEThe Changing Incidence of Femoral Artery
Pseudoaneurysm
We read with interest the article by Norwood and
colleagues.1
The management of femoral artery pseudoaneur-
ysm has evolved in recent years and percutaneous
ultrasound guided thrombin injection is now rec-
ommended as the standard of care. Its efficacy is
highlighted by successful pseudoaneurysm thrombo-
sis in 96% of cases and good patient tolerance.2,3
As described by Norwood, potential reasons for a
change in femoral artery pseudoaneurysm incidence
may be related to an increased number of interven-
tional cardiological procedures performed coupled
with the newer anti-platelet agents now employed.
We have recently undertaken a review of 87 patients
with89 iatrogenic pseudoaneurysm treated at our centre
between January 1997 and June 2002.4 Thrombin
injection was introduced as a treatment modality from
July 1999. Prior to this, compression therapy and
conventional operative repair were utilised in the
management of pseudoaneurysm. In the two years
(1997–1998) before the introductionof thrombin therapy,
17 (89%)of 19 lesionswere repaired surgically. In the two
years (2000–2001) after its introduction, 21 (41%) of 51
required operation. While there was no significant
increase in the total number of arterial catheterisations,
therewere significantlymore pseudoaneurysms treated
after July 1999; thepoint atwhich thrombin injectionwas
introduced as a treatment option.
Findings of an increased number of pseudoaneur-
ysms referred and treated together with a constant
incidence of surgical repair for pseudoaneurysm
suggest that a lower threshold for treatment by
thrombin injection exists; and may account for the
increased incidence seen in our series and that of
Norwood and colleagues.
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Arterial pseudoaneurysms are extremely rare findings
in human immunodeficiency virus (HIV) infected
patients. However, prolonged survival and the
accumulation of cardiovascular risk factors (i.e. ather-
osclerosis, arterial blood hypertension, dyslipidemia)
observed in patients on highly active antiretroviral
regimens (HAART) can lead to an increased risk of
vascular complications.1–3
We report here the case of a 56-year-old bisexual
man, HIV-infected since June 1991, never followed at
any HIV care centre until November 1997, when he
developed cerebral toxoplasmosis. After hospitaliz-
ation, HAART containing stavudine, didanosine and
indinavir was started with immunological and virolo-
gical improvement (November 1997, CD4C: 9
cell/mmc, HIV-RNA: 66460 copies/ml, measured by
NASBA technique; July 1998, CD4C: 187 cell/mmc,
HIV-RNA: 4340 copies/ml). HIV-RNA plasma levels
became undetectable in December 1998 and since then
plasma viremia remained below detection limits;Eur J Vasc Endovasc Surg 28, 451–454 (2004)
doi:10.1016/j.ejvs.2004.07.004, available online at http://www.sciencedirect.com onved.
Fig. 1. Pulsatile hematoma of the femoral artery pre (a) and
post (b) surgical intervention.
Correspondence452CD4Ccell count have been stable above 250/mmc
since November 1999. In the following years, the
patient experienced a progressive worsening of
metabolic parameters refractory to fibrates- statine-
and sulfonylureas-containing therapy (October 2000:
triglycerides: 1014 mg/dl; total cholesterol:
215 mg/dl; HDL cholesterol: 20 mg/dl; glucose:
155 mg/dl) and developed a progressive lipoatrophy.
Moreover, arterial blood hypertension was diagnosed
and in December 2000 enalapril was started; a carotid
ultrasound examination was then performed and no
alterations were found. In January 2001, indinavir was
replaced by efavirenz with a reduction of triglycerides
(291 mg/dl) and glucose (121 mg/dl), whereas choles-
terol remained stable. In May 2003, efavirenz was
replaced by atazanavir due to persistant hyperlipidae-
mia. Immunovirological and metabolic parameters
remained unaltered (CD4: 275 cell/mmc; HIV-RNA!
50 copies/ml; triglycerides: 277 mg/dl; total choles-
terol: 184 mg/dl; HDL cholesterol: 23 mg/dl; glucose:
237 mg/dl).
In March 2004, the patient was admitted to our
clinic for cough and fever: right basal pneumonia
was diagnosed by chest radiography and Strepto-
coccus Pneumoniae isolated in both blood and
sputum culture; antibiotic treatment with intrave-
nous ceftriaxone was started with rapid clinical
improvement. During hospitalization, a pulsatile
mass was detected in the right inguinal region and
a color-doppler ultrasound examination revealed a
pseudo-aneurysm of the right femoral artery.
During the surgical exploration a 2 cm laceration
of a pulsatile hematoma was identified in the
anterior wall of the right femoral artery close to the
artery bifurcation (Fig. 1(a)). A bovine pericardium
patch was inserted to repair the damaged wall
(Fig. 1(b)). Cultural examinations on surgical
samples for fungi and bacteria were negative.
Seven days later, an hemorrhage suddenly devel-
oped and an emergency surgery was executed to
suture a 2–3 mm laceration located on the same site.
Six days later, another hemorrhage developed and a
second emergency operation was performed. At
macroscopic pathologic examination, a complete
destruction of the commune, superficial and deep
femoral arteries (7 cm of length) was observed; the
artery showed soft consistency and several necrotic
areas. The necrotic tract was removed and substituted
with a prosthesis in PTFE-e. Microbiological and
pathological examinations of perianeurismatic fluid
and artery confirmed the presence of several necrotic
areas, but the cultural examinations for bacteria,
mycobacteria and fungi were still negative.
During hospitalization, a color-doppler ultrasoundEur J Vasc Endovasc Surg Vol 28, October 2004examination of carotid vessels was performed, show-
ing a bilateral thickening of the tunica intima of the
common carotid arteries.
The possible role of antiretroviral drugs in inducing
such alterations was finally considered and stavudine
and didanosine were replaced by zidovudine and
lamivudine, whereas atazanavir was maintained.
Several reports have recently emphasized the
higher risk of HIV infected patients to develop
cardiovascular pathologies.4,5 A modification of
dietary habits and lifestyle has to be carefully
evaluated in this population. A periodical vascular
screening should be performed by ultrasound
examinations6 and, when possible, a modification
of antiretroviral therapy should be considered,
especially for patients with metabolic abnormalities
and lypodistrophy.
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http://www.sciencedirect.com onCurrent Treatment Options for Treating Primary
Hyperhidrosis
We read with interest the comprehensive review
article by Nyamekye.1 Some of the complications of
treating hyperhidrosis using endoscopic thoracic
sympathectomy, however, have not been fully dis-
cussed. In a recent review article by Ojimba and
Cameron,2 significant complications of this procedure
highlighted include death, (though as highlighted by
the author never actually reported in the literature),
bleeding, neuralgia and rebound sweating. The other
problem, which has been highlighted is compensatory
sweating which the authors have reported is probably
more prevalent than actually reported. The patients
who died from anaesthetic complication were those* In order to avoid possible confusion between the terminology used
by the Authors and that suggested in #7, in this letter, the veins of the
lower limb are designated with the original Latin terms.who had a double lumen endotracheal tube to allow
both sides to be operated on at the same operation,
which lead to hypoxia of the brain. Our experience is
to use a similar endotracheal anaesthesia and but to
only to perform this operation on one side at a time. As
well as reducing the possible anaesthetic risk also
allows the patients to experience any side effects
especially the compensatory sweating. If this is
troublesome then the patient may have no wish to
have the other side done.
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I read with great interest the article from Dr MacK-
enzie and coll. entitled ‘The effect of Long Saphenous
Vein stripping on deep venous reflux’ (EJVES 2004; 28:
104–107) which confirms that radical surgery of
varicose veins enhance deep veins hemodynamics.
The authors evaluated deep venous hemodynamics at
the thigh by insonating only the Vena Femoralis.* Their
findings would be further enhanced by extending
Duplex evaluation to the Vena Femoralis Communis,
due to its closer hemodynamic interdependency with
of the proximal Vena Saphena Magna.1
The authors reported a ‘surprisingly common fail-
ure to obtain complete stripping’ of the Vena Saphena
Magna after its stripping to the knee. In 62% of limbs,
the postoperative Duplex demonstrated remnants of
various length ‘.of the Vena Saphena Magna
removed in the thigh’.
This intriguing and apparently paradoxical finding
could be explained by the particular anatomy of thigh
superficial veins. The classic studies of Glasser,2Eur J Vasc Endovasc Surg Vol 28, October 2004
